An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus

Journal of Medicinal Chemistry

Volumn 46, Issue 15, 2003, Pages 3181-3184

  Watson, Keith G ^a,d   Brown, Renee N ^a   Cameron, Rachel ^a   Chalmers, David K ^a   Hamilton, Stephanie ^a   Jin, Betty ^a   Krippner, Guy Y ^a   Luttick, Angela ^a   McConnell, Darryl B ^a   Reece, Phillip A ^b   Ryan, Jane ^b   Stanislawski, Pauline C ^a   Tucker, Simon P ^b   Wu, Wen Yang ^a   Barnard, Dale L ^c   Sidwell, Robert W ^c  

^a MONASH UNIVERSITY   (Australia)

^b Biota Holdings Limited   (Australia)

^c UTAH STATE UNIVERSITY   (United States)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OXIME DERIVATIVE; PIRODAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG BIOAVAILABILITY; DRUG SCREENING; HUMAN RHINOVIRUS; IC 50; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; VIRUS STRAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CAPSID; CELL LINE; ETHERS; FEMALE; HUMANS; MALE; MICE; OXIMES; PIPERIDINES; PROTEIN BINDING; PYRIDAZINES; RATS; RHINOVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038155355     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0202876     Document Type: Article

References (27)

1. Makela, M. J.; Puhakka, T.; Ruuskanen, O., et al. Viruses and bacteria in the etiology of the common cold. J. Clin. Microbiol. 1998, 36, 539-542.
2. Turner, R. B. The common cold. Pediatr. Ann. 1998, 27, 790-795.
3. Arruda, E., Hayden, F. G. Clinical Studies of Antiviral Agents for Picornaviral Infections. In Antiviral Chemotherapy; Jeffries, D. J., De Clercq, E., Eds.; John Wiley & Sons: New York, 1995; pp 321-355.
4. McKinlay, M. A.; Pevear, D. C.; Rossman, M. G.; Treatment of the Picornavirus Common Cold by Inhibitors of Viral Uncoating and Attachment, Annu. Rev. Microbiol. 1992, 46, 635-654.
5. Tebbe, M. J.; Spitzer, W. A.; Victor, F.; Miller, S. C.; Lee, C. C.; Sattelberg, T. R.; McKinney, E.; Tang, J. C. Antirhino/Enteroviral Vinylacetylene Benzimidazoles: A Study of Their Activity and Oral Plasma Levels in Mice. J. Med. Chem. 1997, 40, 3937-3946.
6. 1 Lactam Moieties as L-Glutamine Replacements. J. Med. Chem. 1999, 42, 1213-1224.
7. (a) Hayden, F. G.; Kim, K.; Coats, T.; Blatter, M.; Drehobl, M. Pleconaril Treatment Shortens Duration of Picornaviral Upper Respiratory Illness in Adults. In Abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September, 2000, Toronto. Abstract 1161.
8. (b) See www.viropharma.com/healthcare/clinical.html.
9. For selected examples, see: (a) Hadfield, A. T.; Diana, G. D.; Rossman, M. G. Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14730-14735.
10. (b) Oren D. A.; Zhang, A.; Nesvadba, H.; Rosenwirth, B.; Arnold, E. Synthesis and Activity of Piperazine-containing Antirhinoviral Agents and Crystal Structure of SDZ 880-061 bound to Human Rhinovirus 14. J. Mol. Biol. 1996, 259, 120-134.
11. (c) Giranda, V. L.; Russo, G. R.; Felock, P. J.; Bailey, T. R.; Draper, T.; Aldous, D. J.; Guiles, J.; Dutko, F. J.; Diana, G. D.; Pevear, D. C. Structures of Four Methyltetrazole-Containing Antiviral Compounds in Human Rhinovirus Serotype 14. Acta Crystallogr. 1995, D51, 496-503.
12. Diana, G.; Jaeger, E. P.; Peterson, M. L.; Treasurywala, A. M. The use of an algorithmic method for small molecule super-impositions in the design of antiviral agents. J. Comput.-Aided Mol. Design 1993, 7, 325-335.
13. Giranda, V. L.; Diana, G. D. Rhinoviral Capsid-Binding Inhibitors: Structural Basis for Understanding Rhinoviral Biology and for Drug Design. In Structure-Based Drug Design; Veerapandian, P., Ed.; Marcel Dekker Inc.: New York, 1997; pp 487-524.
14. Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Van Eemeren, K.; Stokbroekx, R.; Janssen, P. A. J. In-Vitro Activity of Pirodavir (R 77975), a Substituted Phenoxy-Pyridazinamine with Broad-Spectrum Antipicornaviral Activity. Antimicrob. Agents Chemother. 1992, 36, 100-107.
15. Andries, K. Discovery of Pirodavir, a Broad-Spectrum Inhibitor of Rhinoviruses. In The Search for Antiviral Drugs; Adams, J., Merluzzi, V. J., Eds.; Birkhauser: Boston, 1993; pp 179-209.
16. Hayden, F. G.; Andries, K.; Janssen, P. A. J. Safety and Efficacy of Intranasal Pirodavir (R77975) in Experimental Rhinovirus Infection. Antimicrob. Agents Chemother. 1992, 36, 727-732.
17. Hayden, F. G.; Hipskind, G. J.; Woerner, D. H.; Eisen, G. F.; Janssens, M.; Janssen, P. A. J. Andries, K. Intranasal Pirodavir (R77975) Treatment of Rhinovirus Colds. Antimicrob. Agents Chemother. 1995, 39, 290-294.
18. Diana, G. D.; Pevear, D. C. Antipicornavirus drugs: current status. Antiviral Chem. Chemother. 1997, 8, 401-408.
19. A preliminary account of aspects of this work has been reported at the 14th International Conference on Antiviral Research, Seattle, April 8-12, 2001. The oxime ethers are also the subject matter of International Patent Application PCT WO 00/78746.
20. 50 values were determined both visually and by a dye uptake method. The variability of the results between duplicate runs and methods of determination was generally no more than one dilution.
21. Stokbroekx, R. A.; Van der Aa, M. J. M.; Luyckx, M. G. M.; Grauwels, A. J. Pyridazinamine Derivatives. United States Patent 4,992,433; Chem. Abstr. 1990, 112, 35876y.
22. Karabatsos, G. J.; Hsi, N. Structural studies by nuclear magnetic resonance-XI. Conformations and configurations of oxime O-methyl ethers. Tetrahedron 1967, 23, 1079.
23. Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Stokbroekx, R.; Lewi, P. J. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program. Antiviral Res. 1991, 16, 213-225.
24. For reviews of bioisosterism, see: (a) Lipinski, C. A. Bioisosterism in Drug Design. Annu. Rep. Med. Chem. 1986, 21, 283-291.
25. (b) Burger, A. Isosterism and Bioisosterism in Drug Design. Prog. Drug. Res. 1991, 37, 287-371.
26. (c) Patani, G. A.; LaVoie, E. J. Bioisosterism: A Rational Approach in Drug Design. Chem. Rev. 1996, 96, 3147-3176.
27. Bromidge, S. M.; Brown, F.; Cassidy, F.; Clark, M. S. G.; Dabbs, S.; Hadley, M. S.; Hawkins, J.; Loudon, J. M.; Naylor, C. B.; Orlek, B. S.; Riley, G. J. Design of [R-(Z)]-(+)-α-(Methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile (SB 202026), a Functionally Selective Azabicyclic Muscarinic M1 Agonist Incorporating the N-Methoxy Imidoyl Nitrile Group as a Novel Ester Bioisostere. J. Med. Chem. 1997, 40, 4265-4280.